Equity Overview
Price & Market Data
Price: $1.32
Daily Change: -$0.08 / 6.06%
Range: $1.26 - $1.46
Market Cap: $3,051,451
Volume: 113,343
Performance Metrics
1 Week: -5.80%
1 Month: -11.56%
3 Months: -78.30%
6 Months: -91.75%
1 Year: -97.75%
YTD: -90.77%
Company Details
Employees: 4
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.